Natural Products and Derivatives as Leads to Cell Cycle Pathway Targets in Cancer Chemotherapy

被引:121
作者
Newman, David J. [1 ]
Cragg, Gordon M. [1 ]
Holbeck, Susan [2 ]
Sausville, Edward A. [3 ]
机构
[1] NCI, Nat Prod Branch, Bethesda, MD 20892 USA
[2] NCI, Informat Technol Branch, Bethesda, MD 20892 USA
[3] NCI, Off Associate Director, Dev Therapeut Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
关键词
D O I
10.2174/1568009023333791
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The influence of natural products upon drug discovery in general has been quite impressive; one only has to look at the number of clinically active drugs that are in use in cancer therapy to see how many either are natural products or have a natural product pharmacophore. What is now becoming quite apparent is that materials from natural sources are excellent probes (indicators) for cellular targets that when modulated, may well have a deleterious effect upon the cycling of a tumor cell through the conventional cell cycle. If the particular target is not expressed in normal cell cycling, then a directed "perturbation" of the tumor cell's cycle may well lead to a novel method of treatment for specific tumor types. In this review we have not attempted to be exhaustive but have given a current overview of how natural products from marine, microbial and plant sources have permitted in-depth analyses of various parts of the cell cycle under varying conditions with the ultimate aims of attempting to "control or perturb" the cycling of tumor cells in a fashion that permits their ultimate removal via cellular death, with a minimum of trauma to the host.
引用
收藏
页码:279 / 308
页数:30
相关论文
共 196 条
[21]   Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts [J].
Cavazos, CM ;
Keir, ST ;
Yoshinari, T ;
Bigner, DD ;
Friedman, HS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (03) :250-254
[22]   Synthesis and phosphatase inhibitory activity of analogs of sulfircin [J].
Cebula, RE ;
Blanchard, JL ;
Boisclair, MD ;
Pal, K ;
Bockovich, NJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (15) :2015-2020
[23]   14-3-3σ is required to prevent mitotic catastrophe after DNA damage [J].
Chan, TA ;
Hermeking, H ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1999, 401 (6753) :616-620
[24]  
Chehab NH, 2000, GENE DEV, V14, P278
[25]   Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists [J].
Chen, YNP ;
Sharma, SK ;
Ramsey, TM ;
Jiang, L ;
Martin, MS ;
Baker, K ;
Adams, PD ;
Bair, KW ;
Kaelin, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4325-4329
[26]  
Ciomei M., 1997, P AM ASS CANC RES
[27]   Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential [J].
Clarke, PA ;
Poele, RT ;
Wooster, R ;
Workman, P .
BIOCHEMICAL PHARMACOLOGY, 2001, 62 (10) :1311-1336
[28]  
CZECH J, 1995, INT J ONCOL, V6, P31
[29]  
DAMBROSIO M, 1988, HELV CHIM ACTA, V71, P964
[30]   Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways [J].
Damia, G ;
Silvestri, S ;
Carrassa, L ;
Filiberti, L ;
Faircloth, GT ;
Liberi, G ;
Foiani, M ;
D'Incalci, M .
INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (04) :583-588